AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1656181
Drug: rHu‐EPO treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHu‐EPO treatment
Trial: 7110806
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of fenoterol by nebulizer
Trial: 7110806
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of epinephrine followed by 0.75 mg of Sus-Phrine
Trial: 26829066
Drug: Egg phospholipids
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg phospholipids preparation (45 ml, 15 ml 3 times per day)
Trial: 18217220
Drug: Vocational rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocational rehabilitation programs during inpatient treatment
Trial: 22575569
Drug: Propofol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.0 mg/kg IV initially, then adjusted based on response)
Trial: 16156112
Drug: Fentanyl HCl
RxNorm normalized name: fentanyl HCl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl HCl PCTS 40 microg, 6, 18, 36 and 80 doses over 1, 3, 6 and 13.33 hours
Trial: 11982795
Drug: Sodium thiopental
RxNorm normalized name: Thiopental Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium thiopental (5 mg/kg)
Trial: 9516618
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel and concurrent radiation for 6 weeks with no adjuvant chemotherapy
Trial: 9516618
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel and carboplatin with hyperfractionated radiation, followed by two cycles of adjuvant paclitaxel and carboplatin
Trial: 9516618
Drug: Concurrent weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Concurrent weekly paclitaxel plus radiation
Trial: 9516618
Drug: Paclitaxel, carboplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel, carboplatin, and radiation therapy
Trial: 23024219
Drug: Low phosphate
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low phosphate plus phosphate binder (aluminum hydroxide, 500 mg thrice daily with meals)
Trial: 19387475
Drug: Daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous ghrelin treatment
Trial: 8607589
Drug: Enoxaparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (30 mg subcutaneously every 12 hours)
Trial: 9308789
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg testosterone oenanthate (TE) weekly i.m. injections
Trial: 7871362
Drug: Tactile sensibility
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tactile sensibility of tooth 11 and its antagonists
Trial: 29766842
Drug: Once-daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral antibiotic prophylaxis using either 50 mg of nitrofurantoin, 100 mg of trimethoprim, or 250 mg of cefalexin for 12 months
Trial: 29766842
Drug: Once-daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral antibiotic prophylaxis
Trial: 17075851
Drug: Risedronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (5 mg/day, 15 mg/day, 35 mg/week in Europe, 50 mg/week in North America)
Trial: 10771879
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (100,000 IU) with measles vaccine
Trial: 10771879
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with measles vaccine
Trial: 28669666
Drug: Nutriose®06 (resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutriose®06 (resistant dextrin) 10 g/d for 8 weeks
Trial: 24965504
Drug: Dexpramipexole (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpramipexole (75 mg and 150 mg single doses)
Trial: 16175132
Drug: Pliva Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pliva Cyclosporine Soft Gelatin Capsules (USP Modified)
Trial: 16175132
Drug: Neoral (cyclosporine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral (cyclosporine soft gelatin capsules, USP Modified)
Trial: 12789824
Drug: Betaserc (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaserc (16 mg, 3 times daily before meal)
Trial: 3829014
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy with doxorubicin and vincristine, surgery, or radiotherapy followed by additional chemotherapy with the same drug regimen
Trial: 24726579
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication (olanzapine, perphenazine, quetiapine, risperidone, ziprasidone)
Trial: 20634666
Drug: Full construct
RxNorm normalized name: Alstonia constricta bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full construct vaccine (recombinant fowlpox virus carrying genes for HIV Gag-Pol and IFN-gamma)
Trial: 16164709
Drug: C. indicum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. indicum extract-based cream (n = 125)
Trial: 30008985
Drug: Levocetirizine 5
RxNorm normalized name: Levocetirizine 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 5 mg/day
Trial: 1531215
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy plus etanidazole (2 g/m2 i.v. 30 to 60 min before radiotherapy each Monday, Wednesday, and Friday to 34 g/m2 in 17 doses)
Trial: 2939214
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg twice daily)
Trial: 30321655
Drug: Once-daily GSP301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily GSP301 (665 μg olopatadine and 50 μg mometasone)
Trial: 30321655
Drug: Twice-daily GSP301
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily GSP301 (665 μg olopatadine and 25 μg mometasone)
Trial: 14589256
Drug: Medical care
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical care without physical therapy
Trial: 12879543
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg/day
Trial: 376131
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg 3 times daily) plus Medroxyprogesterone acetate (100 mg once daily)
Trial: 376131
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg 3 times daily)
Trial: 31679821
Drug: OM3-PL/FFA 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM3-PL/FFA 1 g/d
Trial: 31679821
Drug: OM3-PL/FFA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM3-PL/FFA (all doses)
Trial: 19232936
Drug: two mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two mg of butorphanol in 10 mL of normal saline (Group 1)
Trial: 15095233
Drug: Cetirizine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 10 mg q.d. for 6 weeks
Trial: 11546717
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 15 mg and preservative-free morphine 200 microg with fentanyl 0.02 mg
Trial: 11546717
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 15 mg and preservative-free morphine 200 microg without fentanyl (Control group)
Trial: 1115014
Drug: 1.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 g/kg body weight protein intake
Trial: 1115014
Drug: 2.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 g/kg body weight protein intake
Trial: 1115014
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g of protein/day
Trial: 31722153
Drug: Secondary surgical
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary surgical cytoreduction followed by platinum-based chemotherapy
Trial: 18285619
Drug: Lisdexamfetamine in
RxNorm normalized name: Product containing lisdexamfetamine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisdexamfetamine in solution
Trial: 18285619
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg lisdexamfetamine capsule with high-fat meal
Trial: 16540958
Drug: Propofol by
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol by continuous infusion
Trial: 16540958
Drug: Lorazepam by
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam by intermittent bolus administration
Trial: 9175220
Drug: IABP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IABP treatment for 2 hours prior to CPB
Trial: 31221280
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (LS: 3 g/day of dietary sodium chloride)
Trial: 29343128
Drug: brexpiprazole 2-3
RxNorm normalized name: brexpiprazole 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 2-3 mg/day
Trial: 29343128
Drug: quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine XR 150-300 mg/day
Trial: 17686441
Drug: Erlotinib versus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib versus chemotherapy
Trial: 17686441
Drug: Erlotinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib monotherapy in recurrent disease
Trial: 10484950
Drug: Melatonin 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5.0 mg at bedtime
Trial: 10484950
Drug: Melatonin 0.5
RxNorm normalized name: melatonin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 0.5 mg at bedtime
Trial: 10484950
Drug: Melatonin 0.5
RxNorm normalized name: melatonin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 0.5 mg taken on a shifting schedule
Trial: 8733853
Drug: Topical flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical flurbiprofen 0.03% solution applied every 15 minutes for 60 to 75 minutes before surgery
Trial: 8733853
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin 1% suspension applied every 15 minutes for 60 to 75 minutes before surgery
Trial: 6753557
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg 3 times daily)
Trial: 30995295
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment with 2,850 kcal/kg and 16% CP
Trial: 30995295
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment with 2,950 kcal/kg and 16.5% CP
Trial: 30995295
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment with 3,050 kcal/kg and 17.0% CP
Trial: 30995295
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment with 3,150 kcal/kg and 17.5% CP
Trial: 12468909
Drug: Urokinase-heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase-heparin (5000 IU)
Trial: 25676588
Drug: Triptorelin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (120 μg/kg body weight)
Trial: 22091799
Drug: Blue-light LED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue-light LED therapy
Trial: 3300175
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection treatment (CIT)
Trial: 27139012
Drug: FE 999049
RxNorm normalized name: Fe
DrugBank: Ferric cation (DB13949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE 999049 (225 IU subcutaneous dosing)
Trial: 23930726
Drug: Zinc bis-glycinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc bis-glycinate 15 mg once a day for 3 months
Trial: 9755737
Drug: Persistence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persistence of subthreshold depressive symptoms 7 months after initiation of antidepressant therapy
Trial: 1276696
Drug: Intra-amniotic prostaglandin
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic prostaglandin F2 alpha (25 mg repeated in six hours)
Trial: 1276696
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (200 ml 20% NaCl)
Trial: 31943257
Drug: APT-1011 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APT-1011 (2 3-mg orally disintegrating tablets) under hs dosing
Trial: 23336348
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue Plasminogen Activator (0.9 mg/kg, maximum dose 90 mg)
Trial: 29440045
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus rescue medication (RM)
Trial: 29440045
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication (RM) alone
Trial: 20117364
Drug: Clinically managed
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically managed treatment
Trial: 17622343
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa (0.2 mg/kg biweekly)
Trial: 17622343
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta (0.2 mg/kg biweekly)
Trial: 17622343
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (agalsidase alfa and beta)
Trial: 9475315
Drug: Prenatal steroid
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal steroid treatment in preterm babies
Trial: 7947529
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 800 micrograms misoprostol
Trial: 7947529
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen
Trial: 3328682
Drug: Ketanserin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 0.5 mg kg‐1
Trial: 31340751
Drug: Probiotics (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (30 billion CFU of a mixture of six viable strains) taken orally twice daily for six months
Trial: 26903303
Drug: Powder vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder vehicle compound of vitamin D (100,000 IU cholecalciferol)
Trial: 26903303
Drug: Powder vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder vehicle compound of vitamin D
Trial: 26903303
Drug: Oil vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil vehicle compound of vitamin D (100,000 IU cholecalciferol)
Trial: 25784512
Drug: Bococizumab 150
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 150 mg Q14 days
Trial: 25784512
Drug: Bococizumab 300
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 300 mg Q28 days
Trial: 19685930
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with S-1 after D2 resection
Trial: 19685930
Drug: Oral fluoropyrimidines
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral fluoropyrimidines (capecitabine)
Trial: 11151453
Drug: Trastuzumab in
RxNorm normalized name: trastuzumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab in combination with chemotherapy
Trial: 14749694
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg for 2 days and 100 mg for 4 days)
Trial: 7514513
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of human growth hormone (Norditropin) in the abdomen
Trial: 7514513
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of human growth hormone (Norditropin) in the thigh
Trial: 3497572
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg/d) and ergocalciferol (20 micrograms/d) supplementation for 6 months
Trial: 11145360
Drug: Fluoride or
RxNorm normalized name: sodium fluoride Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride or chlorhexidine varnish treatment
Trial: 8598866
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy (intravenous heparin, phenprocoumon, and aspirin)
Trial: 8598866
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (ticlopidine plus aspirin)
Trial: 1412114
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment at 31 degrees C
Trial: 26945662
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Finasteride daily for 4 weeks before TURP
Trial: 6324526
Drug: Photocoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photocoagulation therapy (mild treatment with panretinal, focal or both techniques using short‐pulse, small‐spot xenon arc or argon laser methods)
Trial: 26812052
Drug: Prednisolone 5
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg per day
Trial: 26812052
Drug: Prednisolone 5
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg per day (females)
Trial: 24445121
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied heat at 42°C for 30 seconds daily with allantoin lotion formulation
Trial: 24445121
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied heat at 42°C for 30 seconds daily with allantoin gel formulation
Trial: 404621
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin injection
Trial: 15721015
Drug: Roxithromycin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (400 mg daily for 4 weeks)
Trial: 31167060
Drug: Macrolide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrolide treatment
Trial: 3103424
Drug: Red pepper
RxNorm normalized name: Red pepper
DrugBank: Red pepper (DB14759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red pepper (0.1-1.5 g)
Trial: 3103424
Drug: Black pepper
RxNorm normalized name: Black Pepper
DrugBank: Black pepper (DB10557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black pepper (1.5 g)
Trial: 30253174
Drug: Istradefylline 40
RxNorm normalized name: istradefylline 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istradefylline 40 mg
Trial: 18372428
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of metformin twice daily for 5 days followed by 850 mg twice daily for 5 days
Trial: 23134162
Drug: Intravenous catheter
RxNorm normalized name: intravenous catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous catheter